Clinical associations of anticentromere antibodies and antibodies to topoisomerase i. a study of 355 patients

✍ Scribed by E. S. Weiner; W. C. Earnshaw; J.-L. SeneAcal; B. Bordwell; P. Johnson; N. F. Rothfield

• Publisher: John Wiley and Sons
• Year: 1988
• Tongue: English
• Weight: 827 KB
• Volume: 31
• Category: Article
• ISSN: 0004-3591
• DOI: 10.1002/art.1780310309

✦ Synopsis

Anticentromere antibodies (ACA) and anti-topoisomerase I (anti-top0 I) were assayed in serum samples from 355 patients: 89 with proximal scleroderma; 54 with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility , sclerodactyly , telangiectasias), without proximal scleroderma; 154 with primary and secondary Raynaud's disease; and 58 with other rheumatic diseases, without Raynaud's disease. Sera from healthy control subjects were also assayed. Using immunoblotting techniques, anti-top0 I was detected in 28% of the patients with proximal scleroderma; using immunodiffusion techniques, this antibody was found in only 20% of the same group of patients. Anti-top0 I and ACA were found primarily in patients with scleroderma, CREST syndrome, and Raynaud's phenomenon. ACA identified patients with less severe disease, whereas anti-top0 I identified patients with skin and cardiac involvement and patients with malignancies.

Anticentromere antibodies (ACA) and antibodies to Scl-70 have been described in patients with From the Division of Rheumatic Diseases,